Search PubMed⌕ Search

Biomedical subjects

R R Goodman

Publications and source records attributed to R R Goodman.

54 records · Page 3Linked to original sources

Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.

A series of opiate azines, including naloxonazine, naltrexonazine and oxymorphonazine, produce both a wash-resistant inhibition of 3H-opioid binding and prolonged actions in vivo. Opiate diacylhydrazones synthesized from succinic, adipyl and suberic dihydrazides possess similar actions against 3H-opioid binding. Competition studies measuring inhibition of binding in the presence of the compounds revealed little difference between standard, reversible opiates such as naloxone, oxymorphone and naltrexone and our two series of compounds, the diacylhydrazones and the azines. In these assays, the diacylhydrazones, the azines, oxymorphone, naloxone and naltrexone all inhibited 3H-opioid binding with very similar IC50 values, typically under 5 nM. At concentrations under 5 nM, the inhibition of all the compounds was reversible. At higher concentrations, however, much of the inhibition of the diacylhydrazones and azines was not freely reversible, in distinction to oxymorphone, naloxone and naltrexone. Washing after the incubation of membranes with the naloxone, naltrexone or oxymorphone (50 nM) returned binding to control levels. Despite the extensive washing, the diacylhydrazones, on the other hand, lowered binding by as much as 90%. Mu binding was most sensitive to wash-resistant binding. In general, the longer dihydrazide derivatives produced wash-resistant inhibition more effectively than either the shorter dihydrazide derivatives or the corresponding azines. The ability of these compounds to produce wash-resistant inhibition of binding probably did not result from a bivalent attachment of the ligand to two binding sites at once. Additional assymetric azines and diacylhydrazones unable to bind simultaneously to two sites still produced wash-resistant inhibition of binding.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Light microscopic autoradiographic localization of mu and delta opioid binding sites in the mouse central nervous system.

Much work has been done on opioid systems in the rat CNS. Although the mouse is widely used in pharmacological studies of opioid action, little has been done to characterize opioid systems in this species. In the present study the distribution of mu and delta opioid binding sites in the mouse CNS was examined using a quantitative in vitro autoradiography procedure. Tritiated dihydromorphine was used to visualize mu sites and [3H-d-Ala2-d-Leu5]enkephalin with a low concentration of morphine was used to visualize delta sites. Mu and delta site localizations in the mouse are very similar to those previously described in the rat ( Goodman , R.R., S.H. Snyder, M.J. Kuhar , and W.S. Young, 3d (1980) Proc. Natl. Acad. Sci. U.S.A. 77:6239-6243), with certain exceptions and additions. Mu and delta sites were observed in sensory processing areas, limbic system, extrapyramidal motor system, and cranial parasympathetic system. Differential distributions of mu and delta sites were noted in many areas. Mu sites were prominent in laminae I, IV, and VI of the neocortex, in patches in the striatum, and in the ventral pallidum, nucleus accumbens, medial and midline thalamic nuclei, medial habenular nucleus, interpeduncular nucleus, and laminae I and II of the spinal cord. In contrast, delta sites were prominent in all laminae of the neocortex, olfactory tubercle, diffusely throughout the striatum, and in the basal, lateral, and cortical nuclei of the amygdala. The determination of the differential distributions of opioid binding sites should prove useful in suggesting anatomical substrates for the actions of opiates and opioids.

Animals↗

Autoradiography of [3H]beta-endorphin binding in brain.

The autoradiographic regional localization of [3H]beta-endorphin binding in rat brain differed from that of either [3H]dihydromorphine or [3H]D-Ala2-D-Leu5-enkephalin. Comparisons were made from sequential sections through 3 regions of rat brain: striatum, hypothalamus/thalamus, and brainstem. [3H]beta-endorphin labeled some clusters as well as the subcallosal streak in the striatum, the nucleus accumbens, lamina IV of the cortex, medial regions of the thalamus, hippocampus, inferior colliculus, dorsal raphe, median raphe and pontine nuclei. White matter regions had little binding. Although many of these structures were also labeled with either [3H]dihydromorphine or [3H]D-Ala2-D-Leu5-enkephalin, the overall pattern of [3H]beta-endorphin labeling appeared unique, consistent with the proposal of central epsilon receptors.

Animals↗

Adenosine receptors: autoradiographic evidence for their location on axon terminals of excitatory neurons.

Adenosine receptors were made visible on light microscopy by autoradiography with tritiated cyclohexyladenosine. In the cerebellum, adenosine receptors were absent in Weaver mice, which lack granule cells, and were displaced in Reeler mice, which have displacements of granule cells. Thus, adenosine receptors appear to be located on the axon terminals of excitatory granule cells in the cerebellum. Removal of one eye of a rat depleted adenosine receptors in the contralateral superior colliculus, suggesting that the receptors occur on axon terminals of excitatory projections from retinal ganglion cells. The presence of adenosine receptors on excitatory axon terminals may explain synaptic inhibition by adenosine and the behavioral effects of xanthines.

Adenosine↗

Biochemical and pharmacological evidence for opioid receptor multiplicity in the central nervous system.

Evidence from a variety of experimental models has suggested the existence of mu 1, mu 2 and delta binding sites for morphine and the enkephalins in the central nervous system. Additional biochemical experiments now support this concept of a common high affinity site for opiates and opioid peptides. Mu sites have now been implicated in a number of pharmacological actions, including supraspinal analgesia, prolactin release, and catalepsy, but not in others (spinal analgesia, respiratory depression, and the guinea pig ileum). The hypothesis of mu 1 sites was supported by the unique opioid meptazinol, which selectively bound to mu 1 sites. As expected from its mu 1 binding selectivity, its analgesic actions in the mouse, localized supraspinally, were antagonized by the selective mu 1 antagonist naloxonazine and it had no respiratory depressant actions. Other binding studies suggested the presence of discrete SKF10,047-selective (KD approximately 5 nM) binding sites in rat brain which differed from both kappa sites and the previously reported PCP-binding sigma sites. Additional binding and autoradiographical studies have also implied the presence of beta-endorphin, or epsilon, sites in the CNS.

Analgesia↗

Adenosine receptor localization in rat testes: biochemical and autoradiographic evidence for association with spermatocytes.

[3H]Cyclohexyladenosine ( [3H]CHA) labels adenosine receptors in rat testes. Testicular adenosine receptors are regulated by guanine nucleotides and divalent cations in a similar fashion to brain adenosine receptors. Endocrine manipulations which selectively decrease sperm cells reduce biochemically determined numbers of [3H]CHA labeled adenosine receptors, whereas adenosine receptor number is not affected by manipulations that primarily influence Leydig cells. Autoradiographic analysis of [3H]CHA binding in the rat testes reveals a localization within seminiferous tubules. Receptor related silver grains occur within tubular epithelium as well as in the lumen of tubules but are absent in interstitial tissue and blood vessels. These data suggest an association of adenosine receptors with spermatocytes within the seminiferous tubule epithelium.

Adenosine↗

Solubilized adenosine receptors in the brain: regulation of guanine nucleotides.

Adenosine receptors associated with a reduction of adenylate cyclase and labeled by tritium-labeled cyclohexyladenosine can be solubilized from brain membranes with sodium cholate. Regulation of receptor binding by guanine nucleotides is retained in the soluble state. Influences of cations observed in membrane preparations of adenosine receptors are no longer detected with the solubilized receptors. The apparent retention of a complex of receptors and guanosine triphosphate binding but not cation binding protein in the soluble state may permit a molecular analysis of receptor regulation.

Adenosine↗

Kappa opiate receptors localized by autoradiography to deep layers of cerebral cortex: relation to sedative effects.

Kappa opiate drugs differ from other opiates in their unique sedative actions and lack of cross-tolerance. We have visualized kappa opiate receptors by in vitro autoradiography using the kappa drugs [3H]ethylketazocine ([3H]EKC) and [3H]bremazocine. Though these ligands also label mu and delta opiate receptors, their binding is rendered kappa specific by coincubation with morphine and [D-Ala2, D-Leu5]enkephalin (DADL-Enk) to displace mu and delta interactions, respectively. Labeling patterns with [3H]EKC and [3H]bremazocine are the same and differ markedly from localizations of mu and delta opiate receptors visualized with [3H]dihydromorphine and [3H]DADL-Enk, respectively. The highest density and most selective localization of putative kappa receptors occurs in layers V and VI of the cerebral cortex. In these layers cells are localized which project to the thalamus regulating sensory input to the cortex. Receptors in these layers could account for the unique sedative and possibly analgesic effects of kappa opiates.

Analgesics↗

Guanine nucleotide and cation regulation of the binding of [3H]cyclohexyladenosine and [3H]diethylphenylxanthine to adenosine A1 receptors in brain membranes.

Guanine nucleotides, divalent cations, and sodium differentially regulate agonist and antagonist binding to adenosine A1 receptors in brain membranes. Guanine nucleotides decrease the binding of the adenosine A1 receptor agonist [3H]N6-cyclohexyladenosine ([3H]CHA) to guinea pig and bovine brain membranes by about 50% at 1--3 microM, while not affecting binding of the antagonist [3H]1,3-diethyl-8-phenylxanthine ([3H]DPX) to A1 receptors in bovine brain. GTP decreases the potency of agonists competing for [3H]DPX binding by 3--6 times, without altering the potency of antagonists. This effect can be used to grade experimental substances along an adenosine agonist-antagonist continuum. The 66% inhibition of [3H]CHA binding by 1 mM EDTA, with no change in [3H]DPX binding, suggests that endogenous divalent cations may regulate adenosine receptor interactions. Removal of endogenous divalent cations by EDTA treatment greatly increases the enhancement of [3H]CHA binding by divalent cations. Specific binding of [3H]CHA to guinea pig brain is increased 150--170% by 0.3--1.0 mM Mn2+, Mg2+, and Ca2+ following EDTA preincubation, secondary to an increase in apparent affinity and receptor number. Sodium ions also selectively regulate the binding of [3H]CHA. Sodium decreases [3H]CHA binding 40%, whereas lithium and potassium are ineffective. Sodium does not affect [3H]DPX binding.

Adenosine↗

Autoradiographic localization of adenosine receptors in rat brain using [3H]cyclohexyladenosine.

Adenosine (A1) receptor binding sites have been localized in rat brain by an in vitro light microscopic autoradiographic method. The binding of [3H]N6-cyclohexyladenosine to slide-mounted rat brain tissue sections has the characteristics of A1 receptors. It is saturable with high affinity and has appropriate pharmacology and stereospecificity. The highest densities of adenosine receptors occur in the molecular layer of the cerebellum, the molecular and polymorphic layers of the hippocampus and dentate gyrus, the medial geniculate body, certain thalamic nuclei, and the lateral septum. High densities also are observed in certain layers of the cerebral cortex, the piriform cortex, the caudate-putamen, the nucleus accumbens, and the granule cell layer of the cerebellum. Most white matter areas, as well as certain gray matter areas, such as the hypothalamus, have negligible receptor concentrations. These localizations suggest possible central nervous system sites of action of adenosine.

Adenosine↗

Differentiation of delta and mu opiate receptor localizations by light microscopic autoradiography.

We have observed two discrete populations of opiate receptors that are differently localized in rat brain. Morphine-like (mu) receptors, labeled by 125I-labeled [D-Ala-2MePhe4Met(O)5-ol]enkephalin, are concentrated selectively in lamina IV of the cerebral cortex, certain thalamic nuclei, and the periaqueductal grey, while delta receptors, labeled by 125I-labeled [D-Ala2-D-Leu5]enkephalin, are more diffused, having high densities in cerebral cortex, corpus striatum, amygdala, and olfactory tubercle. Because of similarities in their localizations, we propose that mu and delta receptors are respectively the physiologic receptors for [Met]- and [Leu]enkephalin neurons. These distributions reflect the different physiological functions attributed to mu and delta receptors and thus represent discrete functions of [Met]- and [Leu]enkephalin neurons.

Animals↗

Neurotensin-containing cell bodies, fibers and nerve terminals in the brain stem of the rat: immunohistochemical mapping.

Neurotensin immunoreactive perikarya, fibers and nerve terminals, visualized by the indirect immunohistofluorescent method in colchicine-pretreated animals, are localized in many discrete regions of the rat brain stem. Cell body groups are found in the inner aspect of the substantia gelatinosa of the caudal trigeminal nuclear complex, the nucleus of the solitary tract, the parabrachial nuclei, the locus coeruleus, the dorsal raphé nucleus, the periaqueductal gray matter, and the ventral tegmental area of Tsai. These areas of cell body density are accompanied by concentrations of fibers and terminals, while the occasional positive perikaryon noted in the dorsal cochlear nucleus is accompanied by only sparse fluorescent fiber/terminal patterns. Other brain stem regions, such as the floor of the fourth ventricle and aspects of the caudal ventrolateral reticular formation, possess substantial numbers of fibers and terminals that are not accompanied by cell bodies. Many aspects of this distribution coincide with the brain stem distribution of the enkephalin pentapeptides, though significant differences in localization are also evident. Interactions of neurotensin with other neurotransmitter candidates are also suggested by its presence in areas enriched in norepinephrine, dopamine, serotonin, and substance P. Certain neurotensin localizations suggest an association of the peptide with functional brain systems preferentially involving these regions. In particular periaqueductal gray and substantia gelatinosa neurotensin synapses are plausible sites for the analgesia elicited after intercisternal injection of low doses of neurotensin.

Animals↗

Immunohistochemical mapping of enkephalin containing cell bodies, fibers and nerve terminals in the brain stem of the rat.

Enkephalin immunoreactive perikarya, fibers and nerve terminals, visualized by the indirect immunohistofluorescent method in colchicine-pretreated animals, are localized in many discrete regions of the rat brain stem. These specific immunohistofluorescent patterns are similar after staining with selective primary antisera directed against either methionine-enkephalin or leucine-enkephalin. Cell bodies are found in the substantia gelatinosa and interpolaris zones of the trigeminal nuclear complex, the nucleus of the solitary tract, in the vicinity of the nucleus raphé magnus, in the dorsal cochlear, medial vestibular, and paraolivary nuclei and, dorsal to this last region, in the parabrachial nuclei and the dorsal tegmental nucleus of Gudden, in the periaqueductal gray matter and interpeduncular nucleus and along the borders of the lateral lemniscus and medial geniculate. In some areas, such as the parabrachial region, nucleus of the solitary tract and substantia gelatinosa of the trigeminal nucleus, these perikarya are associated with densities of fibers and terminals. Other regions, such as the dorsal cochlear nucleus and the vicinity of the nucleus raphé magnus, contain cell bodies associated with low densities of processes and terminals. In still other nuclei, such as the nucleus of the facial nerve and the locus coeruleus, fiber and terminal densities without associated cell bodies are evident. Many of these enkephalin localizations can be rationalized on the basis of known actions of opiate drugs and the brain stem distribution of opiate receptors.

Animals↗

Autoradiographic localization of kappa opiate receptors to deep layers of the cerebral cortex may explain unique sedative and analgesic effects.

The pharmacologically defined kappa drug 3H-ethylketazocine (3H-EKC) and 3H-bremazocine bind to unique sites, but also to mu and delta receptors. By displacing mu and delta interactions with morphine and D-Ala2, D-Leu5-enkephalin (DADL) respectively we have visualized selective receptors for 3H-EKC and 3H-bremazocine. These two kappa ligands are localized to sites different from mu and delta receptors labeled with 3H-dihydromorphine (3H-DHM) and 3H-DADL. The highest density and most selective localization of putative kappa receptors occurs in layers V and VI of the cerebral cortex. Cells in these layers project to the thalamus, regulating sensory input to the cortex. These deep cortical kappa receptors may account for the unique sedative and analgesic actions of kappa opiates.

Analgesics↗